The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
Year: 2021
Type: article
Source: Clinical Cancer Research
Authors: Petra Deegen, Oliver Thomas, Olivier Nolan-Stevaux, Shyun Li, Joachim Wahl, Pamela Bogner, Famke Aeffner, Matthias Friedrich, Michael Z. Liao, Katja Matthes, Doris Rau, Benno Rattel, Tobias Raum, Peter Kufer, Angela Coxon, Julie M. Bailis
Institutions: Amgen (Germany), Amgen (United States)
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
Funder: Amgen
OpenAlex ID: W3123424129
